GlobeNewswire·Nov 10, 2026, 7:00 AM ET

Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update

OPGx-BEST1 Cohort 2 dosing is complete with top-line data expected in Q1 2027.
The OPGx-LCA5 Phase 3 registrational trial is fully enrolled with dosing initiation expected in Q4 2026.
FDA cleared the IND for OPGx-RDH12 with Phase 1/2 dosing planned for Q4 2026.
FDA approval of phentolamine ophthalmic solution 0.75% for presbyopia triggered a regulatory milestone payment from partner Viatris Inc.
Opus Genetics reports a cash runway into 2029 to support clinical inflection points & priority review voucher opportunities.
Cash & cash equivalents totaled $89.0 million as of September 30, 2026.
License & collaboration revenue was $1.1 million for the quarter ended September 30, 2026, down from $3.1 million in the prior year period.
R&D expenses increased to $14.5 million for the quarter due to higher manufacturing & clinical costs for IRD programs.
G&A expenses rose to $5.9 million for the quarter primarily driven by higher employee compensation.
Net loss for the quarter ended September 30, 2026, was $46.5 million, or $0.46 per share.
OPGx-BEST1 Cohort 1 showed positive results with clinically meaningful visual function improvements in all five participants.
Andrew Murphy, Ph.D., was added as Chief Scientific Officer & Jamie Lynne Hart as Executive Director of Executive Operations.
The company's pipeline includes seven AAV-based programs with additional candidates targeting MERTK, RHO, CNGB1 & NMNAT1.